Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while UBS Group AG Registered Ordinary Shares trades at $48.13 (market cap $142.70B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 23.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.34% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and UBS Group AG Registered Ordinary Shares for 1 Days on average.
| IOVA | UBS | |
|---|---|---|
Market Cap | $6.04B | $142.70B |
Volume | 14,805,993 | 2,096,090 |
Sector | Health | Financials |
52-Week High | $14.82 | $55.72 |
52-Week Low | $1.81 | $36.41 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.97B | $314.41B |
Dividend Yield | — | 2.34% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
